Aktuellt
SENASTE
Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured additional SEK 372m of growth capital on good terms. As a result the company has secure capital to 2026. We increase our base case to SEK 120 (115) with a Bull Case of SEK 220 (215) and Bear Case of SEK 15 (15).
LÄS MER
